Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02166957
Other study ID # OESORDV
Secondary ID OESORECO
Status Completed
Phase N/A
First received June 12, 2014
Last updated November 23, 2015
Start date November 2012
Est. completion date September 2015

Study information

Verified date November 2015
Source Société Française d'Endoscopie Digestive
Contact n/a
Is FDA regulated No
Health authority France: Comité Consultatif National d'Ethique
Study type Observational

Clinical Trial Summary

Complete esophageal obstructions leads to definitive fasting. The rendez-vous endoscopic approach had already been described for complex stenoses but never for disruption with loss of tissue and SES. Patients and methods: This is a retrospective observationnal study about patients referred for complete esophageal disruption and classified in two groups: 1/ Long disruption (> 5cm), after caustic ingestion or due to an esophageal stripping during SEMS removal; 2/ Short disruption (< 5cm), consecutive to radiation therapy. All the procedures are performed according the anterograde retrograde approach, using CO2 and under X-rays guidance. We report the characteristeristics of the procedures, the efficacy, the time before discharge and refeeding, the complications, and the follow-up, especially the number of dilatation sessions for each group. The hypothesis is that anterograde retrograde endoscopic technique is safe and effective for the management of esophageal disruptions in patients for which the surgical treatment confers a high risk of morbidity and mortality.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date September 2015
Est. primary completion date September 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Esophageal disruption with or without loss of SES

Exclusion Criteria:

- Esophageal Complex stenosis

- Mediastinitis

- Severe sepsis

- Coagulation abnormalities

- Contra-indications to general anesthesia

Study Design

Observational Model: Cohort, Time Perspective: Retrospective


Intervention

Procedure:
Recanalization
All patients received clear and detailed information about the different steps, the benefits and the risks of the procedure they would undergo, and gave an informed consent. The rendez-vous technique shared some common characteristics whatever the etiology and the length of esophageal disruption. First, prior to start the specific endoscopic management, all the patients needed to have undergone a surgical gastrostomy one month earlier in order to allow the retrograde access. This one-month delay was necessary to get it completely healed before using it for the procedure. The principle of the combined anterograde retrograde approach is to get an endoscopic access to both the proximal and distal side of the obstruction in the purpose to achieve better and safer recanalization, which could be carried out with either transillumination or using a needle under x-rays guidance.

Locations

Country Name City State
France APHM, North Hospital, Department of gastroenterology Marseille

Sponsors (1)

Lead Sponsor Collaborator
Société Française d'Endoscopie Digestive

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effectiveness of the rendez vous approach for treating esophageal disruption We evaluate the technical and the clinical success. The technical success is the ability to recanalize the esophagus endoscopically.
The clnical success is the possibility to feed patients.
2 days No
Secondary Number of endoscopic sessions Up to 2 years No
Secondary Time before refeeding 15 days Yes
Secondary Complications Per-operative complications (bleeding, perforations, anesthesiological) and post-operative (infection, bleeding...) 7 days Yes
Secondary Number of endoscopic dilation sessions after recanalization Up to 2 years No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03626350 - Prospective Evaluation of the Efficacy and Safety of Submucosal Endoscopy
Completed NCT05039983 - Study of Epigallocatechin-3-gallate (EGCG) for Supportive and Symptomatic Management in Patients With Esophageal Cancer Phase 1